Cours suspendu

Communiqués scPharmaceuticals Inc.

Actions

SCPH

US8106481059

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 06/10/2025			Varia. 5j.	Varia. 1 janv.
5,670 ^USD	-.--%		-.--%	-

07/10/25	MannKind Corporation finalise l'acquisition de scPharmaceuticals Inc. pour environ 290 millions de dollars	CI
07/10/25	MannKind finalise l'acquisition de scPharmaceuticals	MT

Communiqués

16/09/25	SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH	BU
26/08/25	SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH	BU
25/08/25	MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases	AQ
14/08/25	ScPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111	AQ
07/08/25	ScPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update	AQ
31/07/25	ScPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025	AQ
14/05/25	ScPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update	AQ
07/05/25	ScPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025	AQ
01/05/25	ScPharmaceuticals Announces Participation in Three Upcoming Investor Conferences	AQ
19/03/25	ScPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update	AQ
12/03/25	ScPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025	AQ
06/03/25	ScPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease	AQ
26/02/25	ScPharmaceuticals Announces Participation in Two Upcoming Investor Conferences	AQ
06/02/25	ScPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference	AQ
05/02/25	ScPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference	AQ
13/01/25	ScPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results	AQ
10/01/25	ScPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results	AQ
14/11/24	ScPharmaceuticals : Reports Third Quarter 2024 Financial Results and Provides Business Update Form 8 K	PU
14/11/24	ScPharmaceuticals : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
13/11/24	ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update	AQ
06/11/24	ScPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024	AQ
16/10/24	ScPharmaceuticals to Host Key Opinion Leader Webinar on October 22, 2024	AQ
15/10/24	ScPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024	AQ
04/09/24	ScPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference	AQ
14/08/24	ScPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update	AQ